-
Something wrong with this record ?
Are We Ready for Migrastatics
J. Solomon, M. Raškova, D. Rösel, J. Brábek, H. Gil-Henn
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
20-101-PG
Israel Cancer Research Fund
20210071
Israel Cancer Association
CZ.02.1.01/0.0/0.0/16_019/0000785
Center for Tumor Ecology-Research of the Cancer Microenvironment Supporting Cancer Growth and Spread
NLK
Directory of Open Access Journals
from 2012
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2012-03-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
PubMed
34440616
DOI
10.3390/cells10081845
Knihovny.cz E-resources
- MeSH
- Progression-Free Survival MeSH
- Neoplasm Invasiveness MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Neoplasms drug therapy metabolism mortality pathology MeSH
- Cell Movement drug effects MeSH
- Antineoplastic Agents therapeutic use MeSH
- Endpoint Determination MeSH
- Translational Research, Biomedical MeSH
- Research Design MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Metastasis accounts for the highest mortality rates in solid tumor cancer patients. However, research and development have neglected this most lethal characteristic and, instead, have concentrated on the hallmarks of cancer that make tumor cells highly proliferative and distinctive from nonmalignant cells. The concentration on invasion and metastasis can be one of the most meaningful advancements in cancer investigation. Importantly, metastasis-free survival (MFS) was recently approved by the Food and Drug Administration (FDA) as a novel primary endpoint in clinical trials and has been used to evaluate the prognosis of patients with nonmetastatic castration-resistant prostate cancer and soft tissue sarcoma. This new definition enables to shift the focus of research and development in cancer therapeutics toward metastasis and to change the emphasis from using tumor shrinkage as a benchmark for indicating the efficacy of treatment to using MFS as a more representative endpoint for antimetastatic drugs. This perspective outlines the possibility to use this novel endpoint in other solid cancers, and examples of large clinical trials are given in which MFS is defined as an endpoint and/or in which antimetastatic strategies are being examined. These advances now open the door for the rapid development of antimetastatic therapies, which could be used in combination with standard cytotoxic cancer therapies. With pioneer research on metastasis prevention on the rise and the underlying biomechanisms of tumor cell motility and invasion explored further than ever before, we believe an intensified focus on antimetastatic properties will shape this era of cancer translational research.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004070
- 003
- CZ-PrNML
- 005
- 20220228091856.0
- 007
- ta
- 008
- 220113s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cells10081845 $2 doi
- 035 __
- $a (PubMed)34440616
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Solomon, Jonathan $u Cell Migration and Invasion Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel
- 245 10
- $a Are We Ready for Migrastatics / $c J. Solomon, M. Raškova, D. Rösel, J. Brábek, H. Gil-Henn
- 520 9_
- $a Metastasis accounts for the highest mortality rates in solid tumor cancer patients. However, research and development have neglected this most lethal characteristic and, instead, have concentrated on the hallmarks of cancer that make tumor cells highly proliferative and distinctive from nonmalignant cells. The concentration on invasion and metastasis can be one of the most meaningful advancements in cancer investigation. Importantly, metastasis-free survival (MFS) was recently approved by the Food and Drug Administration (FDA) as a novel primary endpoint in clinical trials and has been used to evaluate the prognosis of patients with nonmetastatic castration-resistant prostate cancer and soft tissue sarcoma. This new definition enables to shift the focus of research and development in cancer therapeutics toward metastasis and to change the emphasis from using tumor shrinkage as a benchmark for indicating the efficacy of treatment to using MFS as a more representative endpoint for antimetastatic drugs. This perspective outlines the possibility to use this novel endpoint in other solid cancers, and examples of large clinical trials are given in which MFS is defined as an endpoint and/or in which antimetastatic strategies are being examined. These advances now open the door for the rapid development of antimetastatic therapies, which could be used in combination with standard cytotoxic cancer therapies. With pioneer research on metastasis prevention on the rise and the underlying biomechanisms of tumor cell motility and invasion explored further than ever before, we believe an intensified focus on antimetastatic properties will shape this era of cancer translational research.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a pohyb buněk $x účinky léků $7 D002465
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a stanovení cílového parametru $7 D023381
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a nádory $x farmakoterapie $x metabolismus $x mortalita $x patologie $7 D009369
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a výzkumný projekt $7 D012107
- 650 _7
- $a translační biomedicínský výzkum $7 D057170 $2 czmesh
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Raškova, Magdalena $u Laboratory of Cancer Cell Invasion, Department of Cell Biology, Charles University, Viničná 7, 128 44 Prague, Czech Republic $u Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Faculties of Charles University, Průmyslová 595, 252 42 Vestec u Prahy, Czech Republic
- 700 1_
- $a Rösel, Daniel $u Laboratory of Cancer Cell Invasion, Department of Cell Biology, Charles University, Viničná 7, 128 44 Prague, Czech Republic $u Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Faculties of Charles University, Průmyslová 595, 252 42 Vestec u Prahy, Czech Republic
- 700 1_
- $a Brábek, Jan $u Laboratory of Cancer Cell Invasion, Department of Cell Biology, Charles University, Viničná 7, 128 44 Prague, Czech Republic $u Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Faculties of Charles University, Průmyslová 595, 252 42 Vestec u Prahy, Czech Republic
- 700 1_
- $a Gil-Henn, Hava $u Cell Migration and Invasion Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel
- 773 0_
- $w MED00194911 $t Cells $x 2073-4409 $g Roč. 10, č. 8 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34440616 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220228091854 $b ABA008
- 999 __
- $a ok $b bmc $g 1751511 $s 1155219
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 10 $c 8 $e 20210721 $i 2073-4409 $m Cells $n Cells $x MED00194911
- GRA __
- $a 20-101-PG $p Israel Cancer Research Fund
- GRA __
- $a 20210071 $p Israel Cancer Association
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000785 $p Center for Tumor Ecology-Research of the Cancer Microenvironment Supporting Cancer Growth and Spread
- LZP __
- $a Pubmed-20220113
